We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
Read MoreHide Full Article
Sarepta Therapeutics, Inc. (SRPT - Free Report) incurred an adjusted loss of $1.42 per share for the third quarter of 2020, wider than the year-ago adjusted loss of $1.14 per share. The wider year-over-year loss can be primarily attributed to a significant rise in operating expenses.
Notably, the adjusted figure excludes one-time items, depreciation & amortization expenses, interest expenses, income tax benefit, stock-based compensation expense and other items. Including all these items, the company incurred a loss of $2.50 per share, wider than the loss of $1.70 in the year-ago quarter. The Zacks Consensus Estimate was pegged at a loss of $1.89 per share.
Sarepta recorded total revenues of $143.90 million, up 45.3% year over year. Revenues beat the Zacks Consensus Estimate of $131.49 million.
Shares of Sarepta were down 2.9% in after-market trading on Nov 5, following the earnings release. However, the company’s shares have increased 12.4% so far this year against the industry’s decrease of 1.2%.
Quarter in Details
Sarepta’s commercial portfolio includes two drugs approved for treating Duchenne muscular dystrophy (“DMD”) — Exondys 51 and Vyondys 53.
The company derived product revenues of $121.4 million, up 22.6% year over year, reflecting higher demand for its drugs. The company stated that COVID-19 had modest impact on sales of its drugs during the third quarter.
The company recorded $22.5 million in collaboration revenues related to its licensing agreement with Roche (RHHBY) for commercialization of its gene therapy candidate, SRP-9001 as DMD therapy in ex-U.S. markets.
Adjusted research and development (R&D) expenses totaled $159.9 million in the third quarter, up 44.7% year over year. The increase was primarily due to increased clinical and manufacturing activities related to its micro-dystrophin programs.
Adjusted selling, general & administrative (SG&A) expenses were $57.2 million, down 4% year over year.
Pipeline Update
Sarepta is on track to receive FDA approval for its third DMD drug — Amondys 45 (casimersen) — in February 2021.
Sarepta is progressing well with the development of the micro-dystrophin gene therapy candidate, SRP-9001, in a phase II study in DMD patients and study data readout remains on track, which is anticipated in the first quarter of 2021. The company plans to initiate an open-label study by year-end to evaluate commercial process material for SRP-9001. In September, Sarepta announced two-year follow up results from a study evaluating single administration of SRP-9001 in DMD patients. Data from the studies demonstrated continued safety and tolerability of SRP-9001 after two years of administration. All patients showed a durable response.
The company plans to start a pivotal study on its other gene therapy candidate, SRP-9003, in 2021 to evaluate it in patients with limb-girdle muscular dystrophy type 2E.In September, Sarepta announced18-month functional data from the ongoing study of SRP-9003, evaluating a single administration of the candidate in LGMD type 2E patients, demonstrating continued functional improvements in the low-dose cohort.Moreover, six-month functional data from the high dose cohort demonstrated improvements from baseline across all functional measures.
Sarepta Therapeutics, Inc. Price, Consensus and EPS Surprise
Some better-ranked stocks from the biotech/drug sector include Emergent Biosolutions Inc. (EBS - Free Report) , miRagen Therapeutics, Inc. and BioLineRx Ltd. . While Emergent sports a Zacks Rank #1 (Strong Buy), miRagen and BioLineRx carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent Biosolutions’ earnings per share estimates have moved up from $6.17 to $8.42 for 2021 in the past 60 days. The company delivered an earnings surprise of 127.41%, on average, in the last four quarters. The stock has risen 79.8% so far this year.
Miragen Therapeutics’ loss per share estimates narrowed from 51 cents to 42 cents for 2021 in the past 60 days. The stock has risen 150% so far this year.
BioLineRx loss per share estimates have narrowed from $1.44 to $1.36 for 2021 in the past 60 days. The company delivered an earnings surprise of 10.36%, on average, in the last four quarters. The stock has risen 25.7% so far this year.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
Sarepta Therapeutics, Inc. (SRPT - Free Report) incurred an adjusted loss of $1.42 per share for the third quarter of 2020, wider than the year-ago adjusted loss of $1.14 per share. The wider year-over-year loss can be primarily attributed to a significant rise in operating expenses.
Notably, the adjusted figure excludes one-time items, depreciation & amortization expenses, interest expenses, income tax benefit, stock-based compensation expense and other items. Including all these items, the company incurred a loss of $2.50 per share, wider than the loss of $1.70 in the year-ago quarter. The Zacks Consensus Estimate was pegged at a loss of $1.89 per share.
Sarepta recorded total revenues of $143.90 million, up 45.3% year over year. Revenues beat the Zacks Consensus Estimate of $131.49 million.
Shares of Sarepta were down 2.9% in after-market trading on Nov 5, following the earnings release. However, the company’s shares have increased 12.4% so far this year against the industry’s decrease of 1.2%.
Quarter in Details
Sarepta’s commercial portfolio includes two drugs approved for treating Duchenne muscular dystrophy (“DMD”) — Exondys 51 and Vyondys 53.
The company derived product revenues of $121.4 million, up 22.6% year over year, reflecting higher demand for its drugs. The company stated that COVID-19 had modest impact on sales of its drugs during the third quarter.
The company recorded $22.5 million in collaboration revenues related to its licensing agreement with Roche (RHHBY) for commercialization of its gene therapy candidate, SRP-9001 as DMD therapy in ex-U.S. markets.
Adjusted research and development (R&D) expenses totaled $159.9 million in the third quarter, up 44.7% year over year. The increase was primarily due to increased clinical and manufacturing activities related to its micro-dystrophin programs.
Adjusted selling, general & administrative (SG&A) expenses were $57.2 million, down 4% year over year.
Pipeline Update
Sarepta is on track to receive FDA approval for its third DMD drug — Amondys 45 (casimersen) — in February 2021.
Sarepta is progressing well with the development of the micro-dystrophin gene therapy candidate, SRP-9001, in a phase II study in DMD patients and study data readout remains on track, which is anticipated in the first quarter of 2021. The company plans to initiate an open-label study by year-end to evaluate commercial process material for SRP-9001. In September, Sarepta announced two-year follow up results from a study evaluating single administration of SRP-9001 in DMD patients. Data from the studies demonstrated continued safety and tolerability of SRP-9001 after two years of administration. All patients showed a durable response.
The company plans to start a pivotal study on its other gene therapy candidate, SRP-9003, in 2021 to evaluate it in patients with limb-girdle muscular dystrophy type 2E.In September, Sarepta announced18-month functional data from the ongoing study of SRP-9003, evaluating a single administration of the candidate in LGMD type 2E patients, demonstrating continued functional improvements in the low-dose cohort.Moreover, six-month functional data from the high dose cohort demonstrated improvements from baseline across all functional measures.
Sarepta Therapeutics, Inc. Price, Consensus and EPS Surprise
Sarepta Therapeutics, Inc. price-consensus-eps-surprise-chart | Sarepta Therapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Sarepta currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech/drug sector include Emergent Biosolutions Inc. (EBS - Free Report) , miRagen Therapeutics, Inc. and BioLineRx Ltd. . While Emergent sports a Zacks Rank #1 (Strong Buy), miRagen and BioLineRx carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent Biosolutions’ earnings per share estimates have moved up from $6.17 to $8.42 for 2021 in the past 60 days. The company delivered an earnings surprise of 127.41%, on average, in the last four quarters. The stock has risen 79.8% so far this year.
Miragen Therapeutics’ loss per share estimates narrowed from 51 cents to 42 cents for 2021 in the past 60 days. The stock has risen 150% so far this year.
BioLineRx loss per share estimates have narrowed from $1.44 to $1.36 for 2021 in the past 60 days. The company delivered an earnings surprise of 10.36%, on average, in the last four quarters. The stock has risen 25.7% so far this year.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>